Unlike patients with tumors that express the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2), who have chemotherapy and targeted therapy options, patients with triple-negative breast cancers (TNBCs), that lack the expression of ER, PR, and HER2, have limited treatment options. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.